SUBSCRIBE: Print / eNewsletter
TKI Famitinib Delays Progression in Advanced Colorectal Cancer
The TKI famitinib was associated with a significant PFS improvement in metastatic colorectal cancer patients, according to the results of a phase II study.
NAPOLI-1: MM-398 Combo Shows Benefit in Metastatic Pancreatic Cancer
Combining MM-398 with 5-FU/leucovorin chemotherapy in metastatic pancreatic cancer patients resulted in improved survival compared with 5-FU/leucovorin alone.
Baseline AFP Levels Affect Ramucirumab Benefit in HCC
Hepatocellular carcinoma patients with baseline alpha-fetoprotein (AFP) levels greater than 400 ng/mL may derive greater benefit from second-line ramucirumab.
Second-Line Ramucirumab Plus Chemotherapy Improved Survival in Metastatic Colorectal Cancer
The addition of ramucirumab to second-line FOLFIRI resulted in a delay in disease progression and improved survival in metastatic colorectal cancer patients.
Vitamin D Levels Linked to Colorectal Cancer Survival
Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with chemotherapy and a targeted agent.
Watch-and-Wait Surgical Approach Safe for Some Rectal Cancers
Rectal cancer patients who completed neoadjuvant therapy with a clinical complete response had similar 4-year survival rates as patients who opted for surgery.
Intense Chemo Plus Avastin Ups Survival in Colon Cancer
Initial treatment with FOLFOXIRI plus bevacizumab in metastatic colorectal cancer patients improved survival over FOLFIRI and bevacizumab by more than 4 months.